suggesting a restoration of brain structure. Phase III trials are fully recruited and ongoing. CAMMS-323 (CAREMS-1) is a rater-blinded study that has randomized over 580 treatment-naive patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback